Ran Nussbaum's most recent trade in Keros Therapeutics Inc was a trade of 10,500 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 4, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Keros Therapeutics Inc | Ran Nussbaum | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 10,500 | 10,500 | - | - | Stock Option (right to buy) | |
| Keros Therapeutics Inc | Ran Nussbaum | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 5,250 | 5,250 | - | 0 | Common Stock | |
| Keros Therapeutics Inc | Ran Nussbaum | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Keros Therapeutics Inc | Ran Nussbaum | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Keros Therapeutics Inc | Ran Nussbaum | Director, Ten Percent Owner | 29 Nov 2022 | 3,539 | 2,284,612 | - | 0 | Common Stock | ||
| Keros Therapeutics Inc | Ran Nussbaum | Director, Ten Percent Owner | 29 Nov 2022 | 3,539 | 0 | - | - | Call Options (obligation to sell) | ||
| Keros Therapeutics Inc | Ran Nussbaum | Director, Ten Percent Owner | 29 Nov 2022 | 1,914 | 0 | - | - | Call Options (obligation to sell) | ||
| Keros Therapeutics Inc | Ran Nussbaum | Director, Ten Percent Owner | 29 Nov 2022 | 1,914 | 1,226,412 | - | 0 | Common Stock | ||
| Keros Therapeutics Inc | Ran Nussbaum | Director, Ten Percent Owner | 29 Nov 2022 | 1,723 | 0 | - | - | Call Options (obligation to sell) | ||
| Keros Therapeutics Inc | Ran Nussbaum | Director, Ten Percent Owner | 29 Nov 2022 | 1,723 | 1,121,045 | - | 0 | Common Stock | ||
| UroGen Pharma Ltd | Ran Nussbaum | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.94 per share. | 21 Oct 2022 | 47,999 | 1,485,168 (7%) | 0% | 5.9 | 285,114 | Ordinary Shares |
| UroGen Pharma Ltd | Ran Nussbaum | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Oct 2022 | 32,723 | 0 | - | - | Stock Option (right to buy) | |
| UroGen Pharma Ltd | Ran Nussbaum | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Oct 2022 | 15,276 | 0 | - | - | Stock Option (right to buy) | |
| UroGen Pharma Ltd | Ran Nussbaum | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2022 | 2,211 | 0 | - | - | Stock Option (right to buy) | |
| UroGen Pharma Ltd | Ran Nussbaum | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 16 Jun 2022 | 2,211 | 1,437,169 (6%) | 0% | 5 | 11,055 | Ordinary Shares |
| Eloxx Pharmaceuticals Inc | Ran Nussbaum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 20,000 | 20,000 | - | - | Stock Options (Right to Buy) | |
| UroGen Pharma Ltd | Ran Nussbaum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 6,817 | 6,817 | - | - | Stock Option (right to buy) | |
| UroGen Pharma Ltd | Ran Nussbaum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 3,183 | 3,183 | - | - | Stock Option (right to buy) | |
| UroGen Pharma Ltd | Ran Nussbaum | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 06 Jun 2022 | 1,030 | 1,434,958 (6%) | 0% | 5 | 5,150 | Ordinary Shares |
| UroGen Pharma Ltd | Ran Nussbaum | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jun 2022 | 1,030 | 0 | - | - | Stock Option (right to buy) | |
| Keros Therapeutics Inc | Ran Nussbaum | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 8,293 | 8,293 | - | - | Stock Options (right to buy) | |
| Keros Therapeutics Inc | Ran Nussbaum | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 8,293 | 8,293 | - | - | Stock Option (right to buy) | |
| Eloxx Pharmaceuticals Inc | Ran Nussbaum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Eloxx Pharmaceuticals Inc | Ran Nussbaum | Director | Purchase of securities on an exchange or from another person at price $ 1.35 per share. | 13 May 2021 | 2,630,487 | 3,679,797 (9%) | 6% | 1.3 | 3,551,157 | Common Stock |
| Eloxx Pharmaceuticals Inc | Ran Nussbaum | Director | Purchase of securities on an exchange or from another person at price $ 1.35 per share. | 13 May 2021 | 1,422,222 | 1,989,551 (4%) | 3% | 1.4 | 1,920,000 | Common Stock |
| Eloxx Pharmaceuticals Inc | Ran Nussbaum | Director | Purchase of securities on an exchange or from another person at price $ 1.35 per share. | 13 May 2021 | 1,280,624 | 1,791,470 (4%) | 3% | 1.3 | 1,728,842 | Common Stock |
| Eloxx Pharmaceuticals Inc | Ran Nussbaum | Director | Purchase of securities on an exchange or from another person at price $ 1.35 per share. | 13 May 2021 | 592,592 | 616,592 (1%) | 1% | 1.3 | 799,999 | Common Stock |
| UroGen Pharma Ltd | Ran Nussbaum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 6,817 | 6,817 | - | - | Stock Option (right to buy) | |
| UroGen Pharma Ltd | Ran Nussbaum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 3,183 | 3,183 | - | - | Stock Option (right to buy) | |
| UroGen Pharma Ltd | Ran Nussbaum | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2021 | 2,211 | 0 | - | - | Stock Option (right to buy) | |
| UroGen Pharma Ltd | Ran Nussbaum | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 25 Mar 2021 | 2,211 | 1,433,928 (6%) | 0% | 5 | 11,055 | Ordinary Shares |
| UroGen Pharma Ltd | Ran Nussbaum | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 25 Mar 2021 | 1,030 | 1,431,717 (6%) | 0% | 5 | 5,150 | Ordinary Shares |
| UroGen Pharma Ltd | Ran Nussbaum | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2021 | 1,030 | 0 | - | - | Stock Option (right to buy) | |
| Keros Therapeutics Inc | Ran Nussbaum | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 50.00 per share. | 17 Nov 2020 | 26,634 | 2,288,151 | - | 50 | 1,331,700 | Common Stock |
| Keros Therapeutics Inc | Ran Nussbaum | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 50.00 per share. | 17 Nov 2020 | 14,400 | 1,228,326 | - | 50 | 720,000 | Common Stock |
| Keros Therapeutics Inc | Ran Nussbaum | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 50.00 per share. | 17 Nov 2020 | 12,966 | 1,122,768 | - | 50 | 648,300 | Common Stock |
| Keros Therapeutics Inc | Ran Nussbaum | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 50.00 per share. | 17 Nov 2020 | 6,000 | 155,262 | - | 50 | 300,000 | Common Stock |